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Transdermal testosterone gels are used in the treatment of hypoandrogenism of males. Virilization due to exposure to testosterone
gels has been reported in children resulting in a US Food and Drug Administration (FDA) warning about secondary exposure
to these products. At present, we are unaware of prenatal virilization associated with unintentional testosterone gel exposure. We
report prenatal virilization in a female infant due to secondary maternal exposure to the father’s testosterone gel. We also describe
postnatal virilization of the child’s twin sister.
1.Introduction
Transdermal testosterone gels are used in the treatment of
hypoandrogenism of males [1]. Virilization due to exposure
to testosterone gels has been reported in children ranging
from 9 months to 5 years of age [2–6]. In May 2009, the
US Food and Drug Administration (FDA) issued a warning
for testosterone gel products (AndroGel 1% and Testim
1%), alerting prescribers about secondary exposure to these
products [7]. Based on interrogation of medical literature
databases, at present we are unaware of prenatal virilization
associated with unintentional testosterone gel exposure. We
now report prenatal virilization of a female infant due to
secondary maternal exposure to the father’s testosterone gel.
We also describe postnatal virilization of the child’s twin
sister.
2. Case Presentation
Dizygotic twin girls were born after a 30-week gestation.
Pregnancy was complicated by premature labor at 26 weeks
of gestation requiring 12mg betamethasone treatment for
two days. Medications taken during pregnancy were Well-
butrin, Pepcid, Procardia, and Indocin. The birth weight for
Twin A was 1700gm and Twin B was 1660gm.
Twin A required intubation and mechanical ventilation
for 4 days followed by continuous positive airway pressure
(CPAP) until day of life 8. Twin B required CPAP for
8 days. Both infants had apnea of prematurity and mild
hyperbilirubinemia. The infants were discharged to home at
37 weeks post conception age.
At birth, Twin A was found to have clitoromegaly (2.3 ×
1.7cm) [8] and was Prader Stage 2. Twin B did not have
clitoromegaly (0.3 × 0.1cm). The urethral openings of the
twins were at the base of the phallus.
At 96hours of age, the total testosterone of the virilized
twin was 9.8ng/dL (0.4nM), androstenedione was 71ng/dL
(2nM), and the 17-hydroxyprogesterone was 82ng/dL
(2.4nM) (Table 1; hormonal determinations performed at
Esoterix Laboratory Services, Casablanca Hills, CA).
Transabdominal ultrasound showed normal Mullerian
structures with no evidence of persistent Wolﬃan structures.
The uterus measured 2.9 × 0.67 × 1.2cm with normal
endometrial stripe for age measuring of 0.6cm. The kary-
otypewas46,XX.Anadrenocorticotropichormone(ACTH)
stimulation test yielded normal results at 10 days of age.
At12monthsofage,thecirculatingtestosteronelevelwas
103ng/dl (4nM). A pelvic ultrasound showed no adrenal or
ovarian masses. An ACTH stimulation test revealed an ele-
vated baseline testosterone level but no other abnormalities.2 International Journal of Pediatric Endocrinology
Table 1: Diagnostic test results for twin A.
Chronologic age
Twin A (months)
Ref.
Range # 0.1 12 18 22 23∗ 25∗∗ 29 34 38
Total testosterone ng/dL
(nM)
<3–10
(0.07–0.4)
9.8
(0.4)
103
(4)
46
(1.8)
129
(5.2)
115
(4.8)
217
(8.7)
4.6
(0.18)
13
(0.5)
2.3
(0.09)
Androstenedione ng/dL
(nM)
<10–17
(0.3–0.6)
71
(2.0)
64
(1.9)
46
(1.4)
55
(1.6)
<10
(<0.03)
17-Hydroxyprogesterone ng/dL
(nM)
3–90
(0.1–3)
82
(2.4)
17
(0.5)
15
(0.45)
14
(0.42)
<10
(<0.3)
17-Hyroxypregnenolone
ng/dL (nM)
14–207
(0.4–7)
135
(4)
Dehydroepiandrosterone ng/dL
(nM)
20–130
(0.6–4)
20
(0.6)
47
(1.4)
83
(2.5)
5-Dehydroepiandrosterone-sulfate
mcg/dL <5–57 11 <10 22
(nM) (<0.1–1.4) (0.44) (<0.4) (0.88)
Cortisol ng/dL
(nM)
3–21
(0.9–7)
3
(0.9)
Renin ng/mL/hr
(<10) 1–6.5 6.0
Estradiol ng/dL
(nM)
<15
(<0.4)
<0.10
(<0.003)
Deoxycorticosterone ng/dL
(nM)
2–34
(0.6–1.0)
<2.0
(<0.06)
DHT ng/dL
(nM)
<3
(<0.3)
35
(1.4)
Bone Age (mo) 15 18 24 36
# Prepubertal reference ranges from Esoterix Laboratory Services, Casablanca Hills, CA.
∗A f t e r0 . 2 5m go fd e x a m e t h a s o n ep e rd a yf o r2w e e k s .
∗∗AndroGel exposure revealed at 25 months of age.
At 22 months, the testosterone level was 129ng/dl (5nM).
An MRI showed normal adrenal gland and ovaries. A trial
of dexamethasone was given to suppress potential adrenal
gland androgen production (0.25mg per day for 2 weeks),
but testosterone levels did not decrease (155ng/dl; 6nM).
At 25 months of age, Twin B presented with cli-
toromegaly and a few pubic hairs. The testosterone level was
50ng/dl (2nM) (Table 2). An ACTH stimulation test and
adrenal pelvic ultrasound studies were normal. A bone age
was the same as the chronological age.
Shortly thereafter, after not previously revealing usage,
thefatherstatedthathehadbeenusingAndroGelthreetimes
a day for several years. The gel was applied on the forearms,
and he cradled the children when they slept in their parent’s
bed.
Thefatherwasadvisedaboutproperprecautionsinusing
AndroGel. At 29 months, testosterone levels had decreased
to 4.6 (0.16nM) and 7.6ng/dl (0.3nM), respectively, in Twin
A and B. At 34 months, testosterone levels increased to 13
(0.5nM)and18.0ng/dl(0.7nM),respectively,inTwinAand
B. It was recommended that AndroGel be discontinued in
favor of parenteral administration.
At 36 months, the parents separated and the mother and
children moved to a new residence. At 38 months, testos-
terone levels were 2.3 (0.09nM) and 3.1ng/dl (0.09nM),
respectively, for Twin A and B. Bone ages were the same as
the chronological age.
3. Discussion
Testosterone products are used in the treatment of hypog-
onadism, which is associated with decreased libido, erectile
dysfunction,reducedmusclemass,andreducedbonedensity
[1, 9]. It is estimated that about 4 million men suﬀer from
this condition in the US, and [9] 1.8 million prescriptions
are written for topical testosterone products annually [10].
When used in the household, children and women
are at risk for secondary, unintentional testosterone gel
exposure [9, 10]. Enlargement of genitalia, precocious pubic
hair development, bone age advancement, and inappro-
priate aggressive and sexual behavior have been reported
in children with secondary testosterone gel exposure [2–
6]. Although, some children have reversal of virilization
following elimination of exposure, advance bone ages and
clitoromegaly have been found to persist [2–6]. Of note,
although the testosterone exposure wassigniﬁcant enough to
induce virilization in both girls, it did not result in bone age
advancement. These observations suggest that the genitalia
a r em o r es e n s i ti v et oe ﬀects of testosterone exposure than the
skeletal system.International Journal of Pediatric Endocrinology 3
Table 2: Diagnostic test results for twin B.
Chronologic age
Twin B (months)
Ref.
Range # 25∗∗ 29 34 38
Total testosterone ng/dL
(nM)
<3–10
(0.07–0.4)
50
(2)
7.6
(2.3)
18.2
(0.7)
3.1
(0.12)
Androstenedione ng/dL
(nM)
<10–17
(0.3–0.6)
31
(0.93)
<10
(0.3)
17-Hydroxyprogesterone ng/dL
(nM)
3–90
(0.1–3)
14
(0.42)
<10
(0.3)
5-Dehydroepiandrosterone-sulfate
mcg/dL
(nM)
<5–57
(<0.1–1.4)
20
(0.8)
21
(0.84)
Bone Age (mo) 24 36
#Prepubertal reference ranges from Esoterix Laboratory Services, Casablanca Hills, CA.
∗∗AndroGel exposure discovered at 25 months of age.
Secondary exposure of women to testosterone gels has
been observed [10]. Women exposed to testosterone gel
can show hirsutism, irregular menses, and mood changes
[10]. The mother of the children in this report, though, did
not manifest signs of androgen excess, including acne or
hirsutism.
Support for the notion that bystander testosterone
exposure resulted in prenatal and postnatal virilization
comes from the exclusion of intrinsic causes of virilization.
ACTH stimulation testing on two occasions was normal,
dexamethasone did not suppress testosterone levels, and
there was no structural ovarian or adrenal pathology. Most
importantlytherewasreductionoftestosteronelevelsinboth
girls when they moved to a new environment.
At present we are not aware of other cases of prenatal
virilization associated with transdermal testosterone expo-
sure. It is interesting that only one of the twins developed
intrauterine clitoromegaly suggesting that individual diﬀer-
ences in placental testosterone transmission or sensitivity to
the hormone played a role here. This notion is supported by
otherstudiesshowingvariablefemaleinfantvirilizationborn
to women with androgen producing tumors or conditions
[11–13].
Our observations suggest that transdermal testosterone
exposure during pregnancy can result in virilization of the
fetus. In addition to concerns about postnatal childhood
secondary testosterone exposure, adverse eﬀects on the fetus
following maternal exposure need to be considered.
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